companies / aktisoncology-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 175,000,000175.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Boston MA | |
| industry | unknown | |
| stage | series-b+ |
Aktis Oncology develops targeted alpha-emitter radiopharmaceuticals using a proprietary miniprotein radioconjugate platform. It serves cancer patients with tumor types previously out of reach of radioligand therapies. Differentiator: miniprotein scaffolds aim to expand the radiopharmaceutical-treatable patient population.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-09-01 | series-b | 175,000,000175.0M | null | ○ |
Nginx, WordPress, MailChimp for WordPress 4.12.5, Yoast SEO 27.6, Genesis theme, Google Analytics, Google Tag Manager, Sassy Social Share 3.3.79, PHP, DoubleClick Floodlight, Contact Form 7 6.1.6, WP Engine
| fact | status | src |
|---|---|---|
| Series B, $175.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |